Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ScandiDos AB's change in receivables for the quarter that ended in Apr. 2026 was kr0.38 Mil. It means ScandiDos AB's Accounts Receivable
declined by kr0.38 Mil
from Jan. 2026 to Apr. 2026 .
ScandiDos AB's change in receivables for the fiscal year that ended in Apr. 2026 was kr2.21 Mil. It means ScandiDos AB's Accounts Receivable
declined by kr2.21 Mil
from Apr. 2025 to Apr. 2026 .
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
ScandiDos AB's Days Sales Outstanding for the
three
months ended in Apr. 2026 was 63.97.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ScandiDos AB's liquidation value for the
three
months ended in Apr. 2026 was kr-3.48 Mil.
ScandiDos AB (OSTO:SDOS) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
ScandiDos AB's Days Sales Outstanding for the quarter that ended in Apr. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ScandiDos AB Change In Receivables Related Terms
ScandiDos AB Change In Receivables Historical Data
* Premium members only.
The historical data trend for ScandiDos AB's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of kr2.21 Mil mean?
ScandiDos AB (OSTO:SDOS) has a Change In Receivables of kr2.21 Mil as of Apr. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for ScandiDos AB and its competitors.
Is ScandiDos AB's Change In Receivables too high?
ScandiDos AB's current Change In Receivables is kr2.21 Mil. Overall, ScandiDos AB has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ScandiDos AB's Change In Receivables compare to ABT and SYK?
ScandiDos AB's Change In Receivables of kr2.21 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for ScandiDos AB and its competitors. ScandiDos AB's current Change In Receivables is kr2.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ScandiDos AB stock overvalued right now?
Based on GuruFocus' analysis, ScandiDos AB (OSTO:SDOS) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.14, compared to a current price of kr0.83 — trading 27.2% below its estimated fair value. The current Change In Receivables is kr2.21 Mil. ScandiDos AB's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For ScandiDos AB (OSTO:SDOS), the current Change In Receivables is kr2.21 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ScandiDos AB (OSTO:SDOS) Overvalued in 2026?
Based on GuruFocus' analysis, ScandiDos AB stock appears to be undervalued.
The current stock price of kr0.83 is trading 27.2% below its estimated GF Value™ of kr1.14.
GuruFocus considers ScandiDos AB to be Modestly Undervalued.
Key valuation signals for OSTO:SDOS:
Change In Receivables: kr2.21 Mil
GF Value™: kr1.14 vs. price of kr0.83 (27.2% below fair value)
No single metric tells the full story. See the OSTO:SDOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ScandiDos AB is engaged in providing radiation therapy for cancer. Its product, Delta4 Phantom+, and its various hardware and software options are at the heart of everything ScandiDos does, from product development and production to marketing, sales, and customer support. With Delta4 HexaMotion ScandiDos has successfully developed a motion platform that recreates the movement of the tumor in six dimensions and independently simulates the patient's breathing movement.
47GF Score
Get the complete analysis for OSTO:SDOS
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SDOS has been successfully added to your 
